Canafenib/Encofenib Indian version price and purchasing reference information

Canafenib/Encorafenib (Encorafenib) is an oral BRAF inhibitor, mainly used to treat BRAF V600 mutation-positive advanced melanoma and some colorectal cancer patients. This drug has just been launched in China, and the purchase channels are not yet fully mature. Hospital pharmacies in some areas may have limited supply, so it may be difficult for patients to purchase Canafenib directly in China. It is recommended that patients consult local hospital pharmacies or professional oncologists before use to learn about available drug purchase channels and the latest price information.

In overseas markets, the European version of the original drug Canafenib has been officially sold. Common specifications include 75mg 42 tablets and 75mg 168 tablets. According to market conditions, the price of each box of these two specifications may reach more than 10,000 yuan and more than 40,000 yuan respectively (subject to exchange rate and channel fluctuations). The price is relatively expensive, and long-term treatment imposes a large financial burden on patients, so reasonable planning needs to be combined with medical insurance or other payment methods.

Currently, no generic version of canafenib has been launched in India, so there are no economical generics available in the Indian market. This means that patients cannot obtain lower-priced generic drugs of Canafenib through Indian channels and still have to rely on the original drug or other overseas sources of generic drugs. For patients who want to reduce drug costs, choosing compliant generic drugs from other countries or paying attention to medical insurance policies may be more practical ways.

At present, the main source of generic drugs of Canafenib is the Laos version. The price of each box is about 4,000 yuan, which is basically the same as the ingredients of the original drug. The Lao version of generic drugs provides patients with a relatively economical choice, but the quality and legality of the drugs should be ensured through formal channels when purchasing, and should be used in conjunction with doctor's advice. In clinical use, patients still need to strictly follow the dosage and course of treatment to ensure efficacy and safety.

Reference materials:https://www.drugs.com/